BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 2, 2023
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Ciba-Geigy claims endothelin converting enzyme inhibitors

Aug. 23, 1996
No Comments

Roche discloses ETA antagonists for circulatory disorders

Aug. 23, 1996
No Comments

Endothelin ETA inhibitors described by Roche

Aug. 23, 1996
No Comments

Further nitric oxide synthase inhibitors from Chugai

Aug. 23, 1996
No Comments

The Wellcome Foundation claims nitric oxide synthase inhibitors

Aug. 23, 1996
No Comments

Nitric oxide synthase inhibitors from Merck & Co.

Aug. 23, 1996
No Comments

BASF reveals NMDA and AMPA antagonists

Aug. 23, 1996
No Comments

5-HT1D antagonists claimed by SmithKine Beecham

Aug. 23, 1996
No Comments

Allelix describes dopamine D4 ligands for schizophrenia

Aug. 23, 1996
No Comments

Allelix Biopharmaceuticals reports selective M1/M2 receptor ligands

Aug. 23, 1996
No Comments
Previous 1 2 … 3423 3424 3425 3426 3427 3428 3429 3430 3431 … 3491 3492 Next

Popular Stories

  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 1, 2023.
  • Joint pain

    Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

    BioWorld Science
    Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • COVID-19 mRNA vaccine vials, syringe

    Japan approves first self-amplifying mRNA COVID-19 vaccine from CSL, Arcturus

    BioWorld
    In a global first, Japan's Ministry of Health, Labor and Welfare has approved CSL Ltd.’s and Arcturus Therapeutics Inc.’s self-amplifying messenger RNA (sa-mRNA)...
  • heart-cardio-data.png

    Avidity, BMS sign $2.3B cardiovascular deal for new RNA class

    BioWorld
    In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing